全球免疫营养信息指数是接受根治性治疗的胃癌患者的独立预后因素。

Global Immune-Nutrition-Information Index Is Independent Prognostic Factor for Gastric Cancer Patients Who Received Curative Treatment.

作者信息

Aoyama Toru, Hashimoto Itaru, Maezawa Yukio, Hara Kentaro, Yamamoto Sosuke, Esashi Ryuki, Tamagawa Ayako, Cho Haruhiko, Tanabe Mie, Morita Jyunya, Numata Masakatsu, Kawahara Shinnosuke, Oshima Takashi, Saito Aya, Yukawa Norio

机构信息

Department of Surgery, Yokohama City University, Yokohama, Japan.

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.

出版信息

Cancer Diagn Progn. 2024 Jul 3;4(4):489-495. doi: 10.21873/cdp.10353. eCollection 2024 Jul-Aug.

DOI:10.21873/cdp.10353

PMID:38962545

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11215449/

Abstract

BACKGROUND/AIM: The aim of the present study was to evaluate the clinical impact of the Global Immune-Nutrition-Information Index (GINI) in patients with gastric cancer (GC) who received curative treatment and to clarify the potential of the GINI as a biomarker.

PATIENTS AND METHODS

Patients who underwent curative resection for GC at Yokohama City University between 2005 and 2020 were selected based on their medical records. The GINI was calculated as follows: GINI=[C-reactive protein × platelet × monocyte × neutrophil]/[albumin × lymphocyte].

RESULTS

A total of 258 patients were included in this study. Of these, 169 patients were categorized into the GINI-low group and 89 into the GINI-high group using a cut-off value of 1,730. The three- and five-year overall survival (OS) rates were 86.4% and 78.4%, respectively, in the GINI-low group, and 66.4% and 58.3% in the GINI-high group (p<0.001). In a multivariate analysis for OS, the GINI was identified as an independent prognostic factor [hazard ratio (HR)=1.772; 95% confidence interval (CI)=1.053-2.979, p=0.031]. Similar results were observed for RFS. In addition, the GINI affected the perioperative clinical course, including postoperative surgical complications and postoperative adjuvant treatment.

CONCLUSION

The GINI is a promising biomarker for the treatment and management of GC.

摘要

背景/目的：本研究旨在评估全球免疫营养信息指数（GINI）对接受根治性治疗的胃癌（GC）患者的临床影响，并阐明GINI作为生物标志物的潜力。

患者与方法

根据病历选择2005年至2020年在横滨市立大学接受GC根治性切除术的患者。GINI的计算方法如下：GINI = [C反应蛋白×血小板×单核细胞×中性粒细胞]/[白蛋白×淋巴细胞]。

结果

本研究共纳入258例患者。其中，使用1730的临界值，169例患者被归类为GINI低分组，89例患者被归类为GINI高分组。GINI低分组的三年和五年总生存率（OS）分别为86.4%和78.4%，GINI高分组分别为66.4%和58.3%（p<0.001）。在OS的多因素分析中，GINI被确定为独立的预后因素[风险比（HR）=1.772；95%置信区间（CI）=1.053 - 2.979，p = 0.031]。无复发生存期（RFS）也观察到类似结果。此外，GINI影响围手术期临床过程，包括术后手术并发症和术后辅助治疗。